spacer
home > ict > spring 2018 > imaging innovations
PUBLICATIONS
International Clinical Trials

Imaging Innovations

In every clinical trial, data rules. In trials for treatments of solid cancerous tumours, much of that critical data relates to the size, type, and appearance of new lesions, whether used as eligibility criteria or as safety or efficacy endpoints. The importance of having clean, accurate measures and objective interpretations of those measures to the success of an oncology trial cannot be overstated.

Ensuring the validity of imaging data points in oncology trials is particularly challenging due to the complexity and variability in acquiring and assessing images. Protocols must set forth the choice of imaging modality, the image acquisition parameters, and the specific protocol for the IV contrast or oral contrast. This will enable the application of more than 10 different assessment criteria.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sophie Winandy is Product Manager at ERT and has more than 10 years of experience working closely with clinical trial sponsors and CROs to identify and implement optimal imaging approaches that accelerate the development of new medical products. Drawing on her training as a Registered Technologist, Magnetic Resonance Imaging, Sophie helped to develop the imaging solutions employed by researchers across hundreds of clinical trials during her tenure at Biomedical Systems (acquired by ERT in 2017).
spacer
Sophie Winandy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ChemAxon and AWS simplify getting scientists moving on the cloud

Listen to a talk by Paul Underwood of AWS introducing Biotech Blueprint, a cloud based solution for cheminformatics. The technology for novel compound registration is provided by ChemAxon.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

PREP 2018: 31st International Symposium and Exhibit on Preparative and Process Chromatography

8-11 July 2018, Hyatt Regency in the Baltimore Inner Harbor, MD, USA

The PREP series of symposia is the most recognized international conference devoted to advances in separation technologies in the field of preparative and process chromatography. Join us for a dynamic and innovative program where experts from around the world will address the latest developments and hottest topics in preparative and process chromatography.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement